Incidence, Predictors, and Outcomes Associated with Hypotensive Episodes among Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial

Background: In PARADIGM-HF, sacubitril/valsartan reduced the composite of CV or HF hospitalization compared with enalapril, but resulted in more hypotensive episodes. Methods: We characterized patients in PARADIGM-HF by whether or not they experienced hypotension (reported as an AE) during study run-in (sequential phases of enalapril 10  mg BID, sacubitril/valsartan 49/51 mg BID, and sacubitril/valsartan 97/103 mg BID) and following randomization. We assessed whether hypotension during run-in modified the efficacy of sacubitril/valsartan for the primary outcome.

Source: Journal of Cardiac Failure - July 23, 2016 Category: Cardiology Authors: Orly Vardeny, Brian Claggett, Jessica Kachadourian, Scott M. Pearson, Milton Packer, Michael Zile, Jean Rouleau, Karl Swedberg, John J.V. McMurray, Scott D. Solomon Source Type: research